Updated: New data from a massive Parkinson’s trial could lead to breakthroughs in drug development
US scientists affiliated with the Michael J. Fox Foundation — named after the Back to the Future actor diagnosed with Parkinson’s disease in 1991 — say they can measure a protein that plays a role in Parkinson’s disease, in a development that foundation CEO Debbie Brooks called “a major breakthrough.”
The study measured a version of alpha-synuclein in patient’s cerebrospinal fluid, which opens up the protein as a biomarker for future diagnostics and drug development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.